Bidding to purchase metabolic medicines biotech Metsera in September got here down to 2 pharmaceutical giants, with Novo Nordisk’s increased provide dropping out to Pfizer’s $4.9 billion worth partially as a result of regulatory and monetary dangers tied to a possible cope with the Danish firm. These dangers stay, however Novo is again with a new unsolicited bid. It’s an analogous deal as earlier than, however Metsera shareholders will get considerably extra assured cash up entrance.
Metsera is now ready to stroll away from Pfizer, saying Thursday it has concluded the brand new Novo provide is superior. Novo is proposing to pay $56.50 in money for every Metsera share, amounting to about $6.5 billion. That worth is a greater than 69% premium to Metsera’s closing inventory worth on Sept. 19, the final buying and selling day earlier than the Pfizer acquisition was introduced. Further payouts are contingent on attaining milestones.
Pfizer is difficult Novo’s provide, however not with extra money. The New York-based pharma large mentioned Novo’s provide can’t qualify as a superior proposal below the phrases of its acquisition settlement with Metsera. Pfizer mentioned it should implement its authorized rights below this settlement.
Metsera is growing weight problems medication in the identical class of medicines as Novo Nordisk’s Wegovy, a peptide drug that mimics intestine hormones to spark metabolic results that result in weight reduction. However Metsera’s GLP-1 medication might provide dosing and manufacturing benefits over Wegovy and Eli Lilly’s Zepbound, the present market leaders. The biotech can also be growing tablet formulations and pursuing extra weight problems targets. In an weight problems market that’s turning into more and more aggressive, Metsera’s applications might stand out within the area, making them enticing to any firm trying to make its mark in metabolic medicines.
Novo was amongst as many as eight corporations that talked with Metsera prior to now yr a couple of potential deal, in keeping with regulatory filings associated to the Pfizer acquisition settlement. “Occasion 1,” now recognized to be Novo, expressed early and constant curiosity. However amongst Metsera’s considerations a couple of cope with Novo was the regulatory danger that this proposed tie-up wouldn’t cross muster with antitrust regulators. For this danger, “Metsera would should be considerably compensated, if it might comply with a transaction with such dangers in any respect,” the corporate mentioned within the submitting.
Novo’s new provide is available in two steps. Cost of $56.50 in money for every Metsera share would come instantly following the signing of a definitive settlement — earlier than regulators even log off on the deal. In alternate, Metsera would problem Novo non-voting most well-liked inventory representing 50% of its share capital. Metsera would then declare a dividend of $56.50 per share in money to be paid to shareholders 10 days later.
Following shareholder and regulatory approvals, the acquisition would proceed to the second step. Metsera shareholders would obtain a contingent worth proper (CVR) that would pay out as much as $21.25 per share in money primarily based on growth and regulatory approval milestones and Novo would purchase the remaining excellent shares of Metsera. The milestones for the CVR are much like these within the Pfizer settlement and would tack on about $2.5 billion to the deal if all are met. The as much as $21.25 per share that Novo is proposing to pay now’s considerably lower than the as much as $37 CVR cost proposed in September, however is consistent with Pfizer’s CVR.
Except for the greenback quantities, Novo’s new proposal is actually the identical deal that Metsera’s board turned down in September. In keeping with the submitting, Metsera’s board acknowledged this deal construction offered larger worth to the corporate’s shareholders than a conventional termination charge payable if the deal doesn’t undergo as a result of regulatory points. However Metsera’s board determined in opposition to Novo’s September provide, noting that regulatory dangers might delay the closing of a deal by as much as two years and the CVR can be paid out solely after a protracted time period, if it’s paid in any respect.
The board’s causes for selecting Pfizer’s provide embrace the understanding of that firm’s monetary phrases and a quicker deal shut. Pfizer anticipated to finish the transaction within the fourth quarter of this yr. Metsera’s board voted to just accept Pfizer’s provide of $47.50 per share, or about $4.9 billion.
In a Thursday analysis word, Leerink Companions analyst David Risinger mentioned it’s unclear why Novo has confidence antitrust regulators would assist its acquisition of Metsera on condition that Novo together with Lilly dominate the marketplace for metabolic medication that mimic intestine hormones. Moreover, the Trump administration’s “America First” insurance policies might play a job in regulatory oversight of a Novo deal for Metsera.
Pfizer’s assertion issued in response to Novo’s new Metsera provide characterizes the deal as an try by an organization with a dominant market place to suppress competitors by taking on an American challenger. Pfizer contends the deal is structured in a means that circumvents antitrust legal guidelines and comes with regulatory and executional dangers.
“The proposal is illusory and can’t qualify as a superior proposal below Pfizer’s settlement with Metsera, and Pfizer is ready to pursue all authorized avenues to implement its rights below its settlement,” the pharma large mentioned.
Like many M&A offers, Pfizer’s settlement with Metsera features a provision barring the biotech from looking for different gives. However the settlement permits Metsera to reply to unsolicited increased gives. Past extra worth to shareholders, the settlement defines a superior firm proposal as one which takes into consideration all phrases and situations, “together with all monetary, regulatory, financing, conditionality, authorized and different phrases and situations.”
Pfizer’s settlement with Metsera stays in impact for now. However the biotech’s notification that it plans to enter a definitive settlement with a superior provide provides Pfizer 4 enterprise days to revise its deal phrases. If Metsera terminates the Pfizer settlement to just accept Novo’s provide, the pact requires the biotech to pay the pharma large a $190 million termination charge.
Photograph: Liselotte Sabroe/Scanpix Denmark/AFP, by way of Getty Photographs